NEW YORK--(Business Wire)--Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry industry is available in its
catalogue.
Stakeholder Insight: Prostate Cancer - Hormone-refractory patients
still waiting for treatment breakthroughs
To order that report:
www.reportlinker.com/p073694/Stakeholder-Insight-Prostate
-Cancer---Hormone-refractory-patients
-still-waiting-for-treatment-breakthroughs.html
For more information, contact Nicolas by email
nbo@reportlinker.com , by phone +33 4 37 65 17 03.
As a result of market dominance by agents such as leuprolide, and
AstraZeneca's Zoladex (goserelin) and Casodex (bicalutamide), there is
little space in the antihormonal therapies market for new competition
unless significant clinical superiority or a unique selling point is
demonstrated.
While Taxotere-based chemotherapy is the established first-line
standard for hormone-refractory prostate cancer, many patients are
still precluded from treatment due to toxicity concerns. This, coupled
with a lack of second-line standard therapy, indicates a major gap in
the market that could be potentially lucrative for drug developers.
Enthusiasm has been shown by key opinion leaders regarding certain
late-phase pipeline products, however, during the time of writing,
publication of negative clinical trial data has meant a dampening of
this optimism. It will therefore be some time before the high unmet
needs in the hormone-refractory prostate cancer market are satisfied.
Identify key factors that influence prescribing patterns for
systemic therapy of prostate cancerExamine the significant unmet needs
in the prostate cancer market and identify opportunities for new
product developmentEnhance commercial positioning by increasing
understanding of current dynamics within the prostate cancer market
CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into the prostate cancer market 3
Contributing experts 5
Related reports 5
Upcoming reports 5
CHAPTER 2 INTRODUCTION AND SCOPE 8
Introduction 8
Coverage of the Stakeholder Insight Survey 8
Disease definition and epidemiology 8
Patient segmentation 8
Drug therapy for prostate cancer 8
Recurrent prostate cancer 9
Hormone-refractory prostate cancer 9
Pipeline products for hormone-refractory prostate cancer 9
CHAPTER 3 COUNTRY TREATMENT TREES 11
Introduction 11
Country treatment trees 12
US 12
Japan 16
France 20
Germany 24
Italy 28
Spain 32
UK 36
CHAPTER 4 DISEASE DEFINITION AND EPIDEMIOLOGY 40
Definition of prostate cancer 40
Prostate cancer 40
The most common cancer type and second leading cause of
cancer-related death in males 40
Histology 40
The majority of prostate tumors are adenocarcinomas 40
Risk factors 41
Older age 41
Race 41
Family history 42
Hormones 42
Dietary factors 42
Symptoms 43
Symptoms frequently occur only at an advanced stage of prostate
cancer 43
Screening and diagnosis 43
Measurement of PSA has proved fairly useful in the detection of
prostate cancer, however, several issues need to be resolved 43
A widespread screening program exists in the US... 44
...however, in Europe, results from the ERSPC trial are necessary
before screening programs can be considered 44
Though PSA screening has been shown useful in Japan, the practice
is not widespread 44
Staging 45
Prostate cancer is staged using the TNM system and a
histologically-based Gleason score 45
Epidemiology of prostate cancer 46
Incidence of prostate cancer 46
Prostate cancer is a tumor associated with older men, therefore
incidence is rising in line with the ageing population 46
Mortality from prostate cancer 47
Potentially asymptomatic disease and a high rate of fatality from
co-morbidities mean mortality from prostate cancer is not especially
high 47
Prevalence of prostate cancer 49
Prevalence is high given the tendency for early diagnosis and low
mortality 49
CHAPTER 5 PATIENT SEGMENTATION 51
Introduction 51
Staging of prostate cancer 51
Staging at diagnosis 51
Around half of all prostate cancer cases are diagnosed at a
localized stage 51
Staging at the time of survey 53
A greater proportion have advanced-stage prostate cancer if
patients at the time of survey are examined 53
One-quarter of all prostate cancer patients have
hormone-refractory disease 55
Differences in staging 55
Urologists encounter more early-stage patients, while medical
oncologists typically treat advanced disease... 55
...however, the difference is minimal in Japan due to its
structure of medical practice 59
CHAPTER 6 INITIAL DRUG THERAPY FOR PROSTATE CANCER 60
Introduction 60
Overview of initial therapy for prostate cancer 60
Localized prostate cancer patients can undergo watchful waiting or
radical prostatectomy 60
Initial treatment of locally advanced and metastatic prostate
cancer constitutes androgen deprivation therapy 61
Initial treatment of prostate cancer 62
Initial use of drug therapy 62
As expected, use of initial drug therapy increases with an
advancing stage of prostate cancer 64
However, a higher than expected proportion of localized stage
patients appear to receive drug therapy 64
A lower proportion than average of locally advanced and metastatic
prostate cancer patients receive initial drug therapy in the US 65
Specific initial drug therapy of prostate cancer 66
Across all stages of prostate cancer 66
LHRH agonist monotherapy and total androgen blockade are the
favored drug regimens used in the initial treatment of prostate cancer
66
Localized prostate cancer 68
LHRH agonist monotherapy is generally sufficient given that an
aggressive approach is not needed while the tumor is localized... 69
...however, in Spain and Japan, total androgen blockade is the
favored initial treatment approach for localized prostate cancer 69
Anti-androgen monotherapy is the third most frequently used drug
regimen for localized tumors due to its lower efficacy than medical
castration 70
Use of cytotoxics with or without antihormonal therapy is very low
in the initial treatment of localized prostate cancer 70
Locally advanced prostate cancer 72
On average, similar trends are seen in the initial treatment of
locally advanced prostate cancer as for localized 73
More locally advanced patients receive TAB than localized
patients, at the expense of use of anti-androgen monotherapy 74
Use of cytotoxics with or without antihormonal therapy is still
low 74
Advanced prostate cancer 74
On average, the majority of advanced prostate cancer patients
appear to receive the more aggressive total androgen blockade regimen
as initial treatment, although this observation is deceptive 75
More advanced disease which may require more aggressive treatment
means the combination of cytotoxics and antihormonal therapy is the
third preferred initial regimen 76
Use of cytotoxics in the initial treatment of prostate cancer is
relatively high across all stages in Germany 78
LHRH agonist monotherapy 78
Use of anti-androgens to counter testosterone flare 78
Use of anti-androgens to prevent testosterone flare from LHRH
agonists increases with a more advanced stage of prostate cancer 78
Use of temporary anti-androgen therapy is, surprisingly, lowest in
the US and Germany, and highest in the UK 80
Use of specific LHRH agonists as monotherapy 83
Leuprolide is the favored LHRH agonist for use as monotherapy
across all stages of prostate cancer due to its availability in a
variety of depot formulations 83
Goserelin is the second preferred LHRH agonist monotherapy across
all stages of prostate cancer 85
Use of the various LHRH agonists varies greatly between countries,
with use of leuprolide highest in the US and use of goserelin highest
in the UK 85
Anti-androgen monotherapy 89
Use of specific anti-androgens as monotherapy 89
Bicalutamide, in varying dosing formulations, is the leading
anti-androgen for use as monotherapy across all stage of prostate
cancer 89
Despite being the only branded product in a heavily genericized
market, Casodex (bicalutamide) remains the leader due to a number of
advantages over its competition 91
Casodex is by far the preferred anti-androgen for use as
monotherapy in each of the seven major pharmaceutical markets 91
Casodex 150mg has had a tumultuous regulatory pathway to date 94
The EPC trial showed that 150mg Casodex daily is suitable for
treatment of locally advanced prostate cancer, but not localized
disease 94
Casodex 150mg is still used in localized prostate cancer,
according to surveyed physicians 95
In Japan, only 80mg Casodex is available, while in the US, only
50mg Casodex is available 95
In the EU, use of Casodex is more fragmented between the 50mg and
150mg formulations 95
Use of flutamide is highest in the US 96
Use of cyproterone and nilutamide are highest in the EU 96
Total androgen blockade 97
Use of specific total androgen blockade regimens 97
A combination of leuprolide and bicalutamide is the top TAB
regimen across all stages of prostate cancer 97
No specific recommendations for TAB regimen are made, therefore
the choice of agents is most likely due to physician preference or
cost 98
In the US and Japan, the top three TAB regimens do not vary by
stage, with the leading combination constituting leuprolide and
bicalutamide 99
More variation is seen in the top three TAB regimens used in each
of the five European countries, although leuprolide or goserelin with
bicalutamide still emerge as the first or second preferred regimen in
all markets 101
Use of specific formulations of LHRH agonists 107
Use of specific formulations as monotherapy or as part of
combination regimens 107
On average across the seven major markets, the three-month depot
version of leuprolide is the leading formulation of LHRH agonist 107
Three-month goserelin emerges as the second preferred formulation
of LHRH agonist 108
Three-month formulations of LHRH agonist are deemed to offer the
most convenience and flexibility to patients 109
In the US, use of alternative leuprolide formulations is favored
110
Triptorelin and buserelin formulations appear in the top three
preferred LHRH agonist formulations only in four of the EU countries
110
CHAPTER 7 RECURRENT PROSTATE CANCER 111
Introduction 111
Overview of therapy for recurrent prostate cancer 111
Treatment of recurrent prostate cancer typically involves further
lines of antihormonal therapy 111
Remission rates 112
Remission rates by stage of disease 112
Remission rates are surprisingly high in the more advanced stages
of prostate cancer, indicating that systemic therapy may offer
sufficient disease control 112
High use of TAB to treat localized disease in Japan may result in
a significantly higher remission rate in these patients 114
Duration of remission 114
Duration of remission is longest in localized prostate cancer
patients and shortest in advanced patients 114
A high proportion of localized patients are initially treated with
drug therapy in Spain, thereby resulting in a higher duration of
remission 116
Relapse rates 116
Patients who relapse following remission 116
As expected, relapse rates are highest among advanced prostate
cancer patients and lowest in localized disease 116
Highest relapse rates in Spain, albeit for no apparent reason 117
Stage of disease present at relapse 118
Due to enhanced detection of rising PSA levels, relapsed disease
can be identified while still at a localized stage 118
Hormone-refractory disease at relapse 120
Patients with more advanced disease may have more aggressive
tumors, potentially placing them at a higher risk of developing
hormone-refractory disease more quickly at relapse 120
Drug therapy for recurrent prostate cancer 122
Use of drug therapy for relapse 122
The majority of prostate cancer patients who relapse go on to
receive further antihormonal and/or cytotoxic therapy 122
Surprisingly, drug therapy for relapsed disease is highest in the
Japan and lowest in the US 123
Specific drug regimens used to treat recurrent prostate cancer 124
Drug therapy following LHRH agonist monotherapy 124
In accordance with treatment guidelines, the majority of patients
receive TAB for relapsed disease after undergoing LHRH agonist
monotherapy as initial therapy 124
Cytotoxic-based regimens are the second preference after LHRH
agonist monotherapy, most likely for those patients with HRPC at
relapse 125
Third choice varies between anti-androgen monotherapy or LHRH
agonist monotherapy depending on the country 126
Drug therapy following anti-androgen monotherapy 126
TAB appears the favored regimen to follow initial anti-androgen
monotherapy 126
On average, LHRH agonist monotherapy appears the second preferred
treatment approach following initial anti-androgen monotherapy,
although in some countries use is equivalent to that of
cytotoxic-based regimens 128
The seven-market average dictates that cytotoxic-based regimens
are the third preferred treatment option following initial
anti-androgen monotherapy 129
Anti-androgen monotherapy in both the initial and second-line
treatment settings has been clinically proven to offer few benefits
129
Drug therapy following total androgen blockade 130
Cytotoxic-based regimens are administered to the majority of
patients who receive initial therapy with TAB 130
Continued TAB appears to be the second most popular approach
following initial TAB therapy, possibly as part of an intermittent
dosing regimen 131
On average, the third favored approach following initial TAB is
LHRH agonist monotherapy, although significant differences occur
between individual countries 132
Drug therapy following cytotoxic-based regimens with or without
antihormonal therapy 133
Cytotoxic-based regimens are not typically used as initial
therapy, therefore second-line treatment is highly fragmented between
countries 133
CHAPTER 8 HORMONE-REFRACTORY PROSTATE CANCER 135
Introduction 135
Overview of therapy for hormone-refractory prostate cancer 135
Taxotere-based chemotherapy forms the first-line standard of care
for HRPC patients 135
Bisphosphonates can be used to prevent the formation of bone
metastases and to alleviate bone pain 136
Optimal second-line therapy for HRPC is yet to be defined 136
Progression to hormone-refractory prostate cancer 137
Patients who progress to hormone-refractory prostate cancer 137
Patients diagnosed with advanced prostate cancer are more likely
to progress to HRPC than earlier-stage patients 137
Duration of antihormonal therapy prior to progression to HRPC 138
Localized patients undergo a longer duration of hormonal therapy
prior to development of HRPC, while advanced patients progress more
quickly 138
Drug therapy for hormone-refractory prostate cancer 140
Use of drug therapy for HRPC 140
Given the aggressive nature of HRPC, approximately three-quarters
of patients receive drug therapy as treatment 140
Highest use of initial drug therapy for HRPC seen in Japan, lowest
use seen in the US 142
First-line drug therapy 142
First-line drug regimens used to treat HRPC 142
Taxotere-based chemotherapy regimens are used heavily across all
seven major pharmaceutical markets in the first-line treatment of HRPC
142
The leading seven-market first-line regimen is Taxotere and
prednisone, which is expected given that this combination has
regulatory approval for treatment of HRPC in the US and EU 144
Single-agent estramustine and single-agent Taxotere see equal use
in the first-line treatment of HRPC when the seven-market average is
examined despite a lack of robust supporting clinical data 145
Greater evidence exists supporting the first-line use of a
Taxotere and estramustine combination in comparison to either agent as
monotherapy 146
Use of secondary hormonal therapy as first-line treatment for HRPC
may still be appropriate in those cases where androgen receptors are
still active 147
Second-line drug therapy 147
Progression from first-line to second-line therapy 147
The majority of HRPC patients progress to second-line therapy,
although variation is shown across the seven major markets 147
Second-line drug regimens used to treat HRPC 149
Use of Taxotere-based regimens is still high in the second-line
treatment of HRPC, although mitoxantrone is also used frequently at
this stage 149
The leading seven-market second-line regimens are single-agent
mitoxantrone and a combination of Taxotere and prednisone, both
administered to equal proportions of HRPC patients 151
Single-agent Taxotere is the third leading second-line regimen for
the treatment of HRPC, most likely due to a lack of other approved
agents 152
Use of single-agent estramustine is still high in the second-line
treatment of HRPC in Japan, as well as in France, Italy and Spain 152
Continued use of a combination of Taxotere and estramustine is
seen in the second-line treatment of HRPC in Japan 152
In Germany, a combination of vinorelbine and estramustine appears
in the top three second-line regimens, most likely due to
vinorelbine's milder toxicities 153
Secondary hormonal therapy is used in the second-line treatment of
HRPC in Italy and the UK, which is somewhat surprising at this late
stage 153
Key prescribing influences 153
Key prescribing influences for drug therapy of HRPC 153
The ability to improve overall survival, symptoms and quality of
life are the leading two influences on prescribing for treatment of
HRPC 153
The third leading prescribing influence concerns side-effect
profiles, which is obviously of significance following improvements to
survival and quality of life 156
The importance of remaining key prescribing influences vary
depending on country-specific issues, with cost issues, method and
frequency of administration and physician product familiarity more or
less of similar weight 156
Relatively high importance of cost issues is expected in the more
cost-conservative UK, but not in the US 156
Method of administration, frequency of dosing and physician
product familiarity are all of similar relevance in each of the seven
markets 156
Pharmaceutical company marketing and services appears to be the
least important key prescribing influence across the seven major
markets 157
CHAPTER 9 PIPELINE PRODUCTS FOR HORMONE-REFRACTORY PROSTATE CANCER
158
Introduction 158
Prostate cancer pipeline overview 158
Key pipeline product profiles 164
Abbott's Xinlay (atrasentan) 165
Spectrum Pharmaceuticals/GPC Biotech's Orplatna (satraplatin) 166
Dendreon's Provenge (sipuleucel-T) 167
Cell Genesys's GVAX 169
Novacea/Schering-Plough's Asentar (calcitriol, DN-101) 170
Northwest Biotherapeutics' DCVax-Prostate 172
Genentech/Roche's Avastin (bevacizumab) 172
Key attributes 174
Key attributes for HRPC pipeline products 174
As expected, the top desired attributes in a pipeline drug for
HRPC is to prolong overall survival duration and improve quality of
life 174
Superiority over the current first-line standard 176
Clinical improvements required for a pipeline drug to be used
ahead of the current first-line standard, Taxotere plus prednisone 176
In order for a pipeline drug to be used in combination with
Taxotere over the current first-line standard, relatively large
improvements in clinical benefits would need to be shown 176
Acceptable price increase for a pipeline drug to be used in
advance of the current first-line standard, Taxotere plus prednisone
177
Physicians speculate that payers are prepared to pay nearly 20%
more for a pipeline drug if survival is increased, even at the expense
of increased toxicity 177
Predicted performance of late-phase pipeline products 178
Pipeline drugs are predicted to have some advantages over the
current standard 178
Taxotere-based regimens are ranked highest in terms of overall
survival and symptom/quality of life improvements, which is expected
given the solid clinical evidence available 180
In terms of side-effect profile, method of administration and
frequency of dosing, pipeline products are all ranked ahead of the
standard Taxotere-based regimen, which is ranked the lowest for each
181
Provenge is ranked highest in terms of side-effect profile 181
Xinlay is ranked highest in terms of method of administration and
frequency of dosing 181
No difference is shown between pipeline products in terms of cost
issues 182
Taxotere and Avastin are ranked higher in terms of pharmaceutical
company services, most likely owing to the large and well-established
nature of their manufacturers 182
Taxotere-based regimens and Avastin were ranked highest in terms
of physician product/class familiarity, which is not surprising, given
these two agents are formally approved for treatment of cancer 183
Brand mapping 183
Interpreting a brand map 183
The brand map confirms the observations made with respect to
predicted performance of pipeline products for HRPC 185
APPENDIX A 186
Physician research methodology 186
Physician sample breakdown 186
US 186
Japan 187
France 187
Germany 188
Italy 188
Spain 189
UK 189
Supplementary data 190
Brand map interpretation 195
Key opinion leader interview transcripts 197
APPENDIX B 198
The survey questionnaire 198
1. Patient segmentation 198
2. Drug therapy for prostate cancer 199
3. Recurrent prostate cancer 209
4. Hormone-refractory prostate cancer 214
5. Pipeline drugs 218
APPENDIX C 221
Bibliography 221
List of tables 230
List of figures 231
List of abbreviations 231
About Datamonitor 233
About Datamonitor Healthcare 233
About the Oncology analysis team 234
Disclaimer 235
To order that report:
www.reportlinker.com/p073694/Stakeholder-Insight-Prostate
-Cancer---Hormone-refractory-patients-
still-waiting-for-treatment-breakthroughs.html
For more information, contact Nicolas by email
nbo@reportlinker.com , or by phone +33 4 37 65 17 03.
More market research reports?
Go to http://www.reportlinker.com
(Long URLs in this release may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one
exists.)
Nicolas
nbo@reportlinker.com
+33 4 37 65 17 03
Copyright Business Wire 2008
